What is more important to me is what happens if the winner goes after big pharma? Would there be any impact on GERN? The entire biotech group has taken a hit already so I wonder if there is anything more out there, or is this all pre-election posturing?
Yes. I recall that he put that idea to bed at the last conference call. It remains a distracting influence on the minds of those who refuse to believe it. The focus is now on the trials.
None of those comparisons matter. First of all, GERN is a different company from what it was a couple of years ago when they changed their focus. Secondly, all that really matters is their success with the current IMET trials. And as the clock ticks, we get closer to a time when those results will be known. With a partner like J&J enabling them to wade through the FDA process and basically underwriting all of the research, they have better prospects than ever before. Those who whine or are critical should know better than to thrust criticism, and are likely placing bets against the company's future success. Complaining about people who are gaming the stock does not matter, nor does taking jabs at the company's progress. We are closer to something that may be a blockbuster, and if the pace is too burdensome for a few, there are plenty of other alternatives out there. IMO, there is base-building going on now, and if the overall market sours, they will not suffer as much as we go forward. In fact, they may become one of the FEW story stocks that folks are willing to channel their funds toward in the next 12 months. GLTA
OK. So is there enough knowledge out there to suggest when we might expect " a scheduled report of preliminary results"? I understand this would depend on having a minimum population that satisfies the trial requirements who have gotten to a point where such results could be publicized. And I would also assume that the FDA has sanctioned the preliminary results conclusions. So roughly when might we have a population far enough through the process, that preliminary results would be expected? 2016? 2017?
Yes, agree. And is it JNJ that issues the reporting of a material event, Geron, or is the info going to come out via one of the primary investigators as late as December? I was hoping we would hear something of substance before that time. If the FDA was encouraged by the early results, might they come out with something to accelerate the process, or would we hear that info through either Geron or JNJ?
Yes, but according to the start dates for the different trials, when is the earliest that JNJ would feel obligated to say something positive? The way it appears, they don't need to say anything until a trial has been completed. It isn't in their interest to pump if the speculation would impact a buy-out price. Didn't we hear that it would be late in the calendar year? Would they wait until the next December hematology conference? Or would someone expect some news sooner? Serious replies please.
You would be well served to not be critical of subjects you know little about. Instead of drinking the Kool-aid of the fossil interests, you might want to understand what goes into building the systems that are sensing the atmospheric variations. The modelling is being continually improved, and the sensing systems that are placed in orbit are highly accurate. The scientists who work on these models and interpret the data could care less which direction the temperatures move. They are more interested in getting the most accurate database and helping industries that depend on predictive capabilities. You might be surprised to know that politics is the last thing on their minds. It only becomes an issue when certain industries try to politicize it.
Why not take your political concerns to a political chat room or join a mercenary group instead of hiding behind a chair. I for one could care less about your slant on the news.
Jack...Tell us something new and pertinent.
1. Your constant griping does not serve your purposes if you are in it for the long term. It may make you feel better but it discourages folks who may be coming to this board for the first time to look for useful information.
2. No one has the capability to influence the price of a stock on these message boards. Certainly, don't take the bait of the jerks who are only here to antagonize. It gives them free advertising.
3. Some folks are doing useful research, and finding new material that promotes GERN's prospects. Lets save the space for them and let the know nothings wither on the vine.
4. We can't prevent the gamers from playing for pennies even though it is antithetical to those who are thinking longer term. Let them feed Uncle Sam or their starving bellies. They will leave once the good news starts coming out. The war is at 5 and once we have staying power over that hump,
these folks will drop away.
5. I am here for the longer term and the prospect that good science will prevail. GLTA longs
Its a chance to flush out the weak hands and hope they go play elsewhere. Nothing has changed insofar as GERN's prospects go. This is more likely a buying opportunity. Not a pump. Just the facts.
We are getting closer to some confirmations of the Mayo findings. That will keep it over 5 and at least a double from here by summer. The more expensive it is, the less chance they will play their game. It could very well be JNJ trying to keep it down so it doesn't get away from them when they decide the time is right.
Nice summary from Mangy. Conversely, beaver offers nothing positive, and one wonders why he is still here stewing in his misery. And he is months past having possibly doubled his money. Should have listened to Mangy but there is still opportunity to make a nice gain this coming year...or to hold for really fabulous gains further out...if one is truly an investor.
I think we are forgetting that there is this thing called fast-track status if the early results are positive. The date information was still useful as a summary, so thanks for that. I have not back-checked it so i will assume it is accurate. . If we get into a PR or CR situation that confirms the Mayo results with the early trials, and there is no competition, the FDA will have to consider acceleration. This in turn will garner more interest/participation and the stock will take off. Nor do the 3 known trials take into account that there may be outside interest in Imetelstat as a combination therapy or as a platform for other entirely new applications once the dosing and safety issues have been put to bed. I think , and this is only my opinion, that barring any negative trial results, that 2016 is the year it begins to go parabolic. Whether JNJ waits it out or not, as soon as good results begin to trickle in, the minimum price point would be whatever the market deems its takeover value would be. I don't think it would be triple digits early on but certainly way higher than where we are now. The trend is clearly positive. And JNJ has some plan to bring it to market early if successful so I think the dates for some applications can be advanced. Meanwhile, it becomes very attractive to other pharma companies and if there is no bidding war, there might be arrangements that Geron/JNJ could make to license applications to others.